Other drugs | Mechanism of action | Clinical use* | Adult dose (usual) | Dose in older adults (≥65 years) | Half-life (hours) | Potential for drug interactions¶ |
Doxepin | Histamine H1 receptor antagonismΔ | Sleep maintenance insomnia | 3 to 10 mg◊ | 3 to 6 mg | Long (15 drug; 31 active metabolite) |
|
Ramelteon | Melatonin receptor agonist | Sleep onset insomnia | 8 mg | 8 mg | Short (1 to 2.6 drug; 2 to 5 active metabolite) |
|
Lemborexant | Dual orexin receptor antagonist (DORA) | Sleep onset or sleep maintenance insomnia | 5 to 10 mg | 5 mg | Long (17 to 19) |
|
Suvorexant | DORA | Sleep onset or sleep maintenance insomnia | 10 to 20 mg | 10 to 15 mg | Intermediate (12) |
|
Daridorexant | DORA | Sleep onset or sleep maintenance insomnia | 25 to 50 mg | 25 to 50 mg | Intermediate (8) |
|
Trazodone§ | Serotonin 5-HT2A, alpha-1 adrenergic, and histamine H1 receptor antagonismΔ | Sleep onset or sleep maintenance insomnia | 50 to 100 mg | 25 to 100 mg | Intermediate (10 to 12) |
|
CYP: cytochrome P450; MAOI: monoamine oxidase inhibitor; FDA: US Food and Drug Administration.
* Appropriate clinical uses may differ from the FDA-approved indication(s) for a given drug.
¶ For specific drug interactions, including management recommendations and combinations that should be avoided, use Lexi-Interact drug interactions program included with UpToDate.
Δ Although classified as antidepressants, these drugs are not therapeutic for treating depression at the doses used for insomnia.
◊ FDA-approved for insomnia at doses of 3 and 6 mg daily using tablet formulation.
§ Not approved by the FDA for insomnia indication.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟